Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2019

01-05-2019 | Breast Cancer | Epidemiology

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

Authors: Tess O’Meara, Anton Safonov, David Casadevall, Tao Qing, Andrea Silber, Brigid Killelea, Christos Hatzis, Lajos Pusztai

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Login to get access

Abstract

Purpose

African-American (AA) patients with triple-negative breast cancer (TNBC) are less likely to achieve pathologic complete response from neoadjuvant chemotherapy and have poorer prognosis than Caucasian patients with TNBC, suggesting potential biological differences by race. Immune infiltration is the most consistent predictive marker for chemotherapy response and improved prognosis in TNBC. In this study, we test the hypothesis that the immune microenvironment differs between AA and Caucasian patients.

Methods

RNA-seq expression data were obtained from The Cancer Genome Atlas (TCGA) database for 162 AA and 697 Caucasian breast cancers. Estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-positive, and TNBC subtypes were included in the analyses. Tumor infiltrating lymphocyte (TIL) counts, immunomodulatory scores, and molecular subtypes were obtained from prior publications for a subset of the TNBC cases. Differences in immune cell distributions and immune functions, measured through gene expression and TIL counts, as well as neoantigen, somatic mutation, amplification, and deletion loads, were compared by race and tumor subtype.

Results

Immune metagene analysis demonstrated marginal immune attenuation in AA TNBC relative to Caucasian TNBC that did not reach statistical significance. The distributions of immune cell populations, lymphocyte infiltration, molecular subtypes, and genomic aberrations between AA and Caucasian subtypes were also not significantly different. The MHC1 metagene demonstrated increased expression in AA ER-positive cancers relative to Caucasian ER-positive cancers.

Conclusions

This study suggests that the immunological differences between AA and Caucasian breast cancers represented by TCGA data are subtle, if they exist at all. We observed no consistent racial differences in immune gene expression or TIL counts in TNBC by race. However, this study cannot rule out small differences in immune cell subtype distribution and activity status that may not be apparent in bulk RNA analysis.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeSantis C et al. (2014) Breast cancer statistics, 2013. CA: A Cancer J Clin 64(1):52–62 DeSantis C et al. (2014) Breast cancer statistics, 2013. CA: A Cancer J Clin 64(1):52–62
2.
go back to reference DeSantis CE et al (2016) Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed DeSantis CE et al (2016) Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed
3.
go back to reference Stark A et al (2010) African ancestry and higher prevalence of triple-negative breast cancer. Cancer 116(21):4926–4932CrossRefPubMed Stark A et al (2010) African ancestry and higher prevalence of triple-negative breast cancer. Cancer 116(21):4926–4932CrossRefPubMed
4.
go back to reference Eric C, Dietze CS, Miranda-Carboni G, Ruth O’Regan, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248–254CrossRef Eric C, Dietze CS, Miranda-Carboni G, Ruth O’Regan, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248–254CrossRef
5.
go back to reference Shinde SS et al (2010) Higher parity and shorter breastfeeding duration. Cancer 116(21):4933–4943CrossRefPubMed Shinde SS et al (2010) Higher parity and shorter breastfeeding duration. Cancer 116(21):4933–4943CrossRefPubMed
6.
go back to reference Lawrence TS, Rosenberg SA (2010) L, Definition of triple-negative breast cancer and relationship to basal-like molecular subtype. In: VT DeVita Jr (eds) PPO updates: principles and practice of oncology. Lippincott Williams & Wilkins, New York, pp 1–6 Lawrence TS, Rosenberg SA (2010) L, Definition of triple-negative breast cancer and relationship to basal-like molecular subtype. In: VT DeVita Jr (eds) PPO updates: principles and practice of oncology. Lippincott Williams & Wilkins, New York, pp 1–6
7.
go back to reference Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI (2017) Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncol 3(12):1654–1662CrossRefPubMedPubMedCentral Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI (2017) Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncol 3(12):1654–1662CrossRefPubMedPubMedCentral
8.
go back to reference Killelea BK et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33(36):4267–4276CrossRefPubMed Killelea BK et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33(36):4267–4276CrossRefPubMed
9.
go back to reference Karn T et al (2015) The influence of host factors on the prognosis of breast cancer: stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets 15(8):652–664CrossRefPubMed Karn T et al (2015) The influence of host factors on the prognosis of breast cancer: stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets 15(8):652–664CrossRefPubMed
10.
go back to reference Bianchini G et al (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and –negative cancers. J Clin Oncol 28(28):4316–4323CrossRefPubMed Bianchini G et al (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and –negative cancers. J Clin Oncol 28(28):4316–4323CrossRefPubMed
11.
go back to reference Adams S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral Adams S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral
12.
go back to reference Wimberly H et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332CrossRefPubMed Wimberly H et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332CrossRefPubMed
13.
go back to reference Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol 8:1679CrossRefPubMedPubMedCentral Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol 8:1679CrossRefPubMedPubMedCentral
14.
go back to reference Safonov A et al (2017) Immune gene expression is associated with genomic aberrations in breast cancer. Can Res 77(12):3317–3324CrossRef Safonov A et al (2017) Immune gene expression is associated with genomic aberrations in breast cancer. Can Res 77(12):3317–3324CrossRef
15.
go back to reference Karn T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L (2017) Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 3(12):1707–1711CrossRefPubMedPubMedCentral Karn T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L (2017) Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 3(12):1707–1711CrossRefPubMedPubMedCentral
16.
17.
19.
go back to reference Rody A et al (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11(2):R15CrossRefPubMedPubMedCentral Rody A et al (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11(2):R15CrossRefPubMedPubMedCentral
20.
go back to reference Callari M et al (2016) Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res 22(2):337–345CrossRefPubMed Callari M et al (2016) Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res 22(2):337–345CrossRefPubMed
21.
go back to reference Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113CrossRefPubMed Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113CrossRefPubMed
22.
go back to reference Esteva FJ et al (2007) CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9(6):R87CrossRefPubMedPubMedCentral Esteva FJ et al (2007) CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9(6):R87CrossRefPubMedPubMedCentral
23.
go back to reference Lennerz V et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018CrossRefPubMedPubMedCentral Lennerz V et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018CrossRefPubMedPubMedCentral
24.
25.
26.
go back to reference Hsiao TH et al (2013) Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol 2013(1):14CrossRefPubMedPubMedCentral Hsiao TH et al (2013) Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol 2013(1):14CrossRefPubMedPubMedCentral
28.
go back to reference Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRefPubMedPubMedCentral Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRefPubMedPubMedCentral
29.
go back to reference Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Peter Kang S, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127(8):2930–2940CrossRefPubMedPubMedCentral Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Peter Kang S, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127(8):2930–2940CrossRefPubMedPubMedCentral
33.
34.
35.
go back to reference Lehmann BD et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentral Lehmann BD et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentral
36.
go back to reference Loi S et al (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22(6):1499CrossRefPubMed Loi S et al (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22(6):1499CrossRefPubMed
37.
go back to reference Luen S et al (2016) The genomic landscape of breast cancer and its interaction with host immunity. The Breast 29:241–250CrossRefPubMed Luen S et al (2016) The genomic landscape of breast cancer and its interaction with host immunity. The Breast 29:241–250CrossRefPubMed
38.
go back to reference Edmund A.Mroza JWR (2013) MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49(3):211–215CrossRef Edmund A.Mroza JWR (2013) MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49(3):211–215CrossRef
39.
go back to reference Chowell D et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587CrossRefPubMed Chowell D et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587CrossRefPubMed
40.
go back to reference Cao K et al (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62(9):1009–1030CrossRefPubMed Cao K et al (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62(9):1009–1030CrossRefPubMed
41.
go back to reference Pitt JJ et al (2018) Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun 9(1):4181CrossRefPubMedPubMedCentral Pitt JJ et al (2018) Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun 9(1):4181CrossRefPubMedPubMedCentral
43.
go back to reference Keenan T et al (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33(31):3621–3627CrossRefPubMedPubMedCentral Keenan T et al (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33(31):3621–3627CrossRefPubMedPubMedCentral
44.
go back to reference Martin DN et al (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 4(2):e4531CrossRefPubMedPubMedCentral Martin DN et al (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 4(2):e4531CrossRefPubMedPubMedCentral
45.
go back to reference Elkhanany A, Katsuta E, Takabe K (2018) Racial disparity in breast cancer immune microenvironment. J Clin Oncol 36(15_suppl):1081–1081CrossRef Elkhanany A, Katsuta E, Takabe K (2018) Racial disparity in breast cancer immune microenvironment. J Clin Oncol 36(15_suppl):1081–1081CrossRef
46.
go back to reference Mu J et al (2014) Regulation of MHC class I expression by Foxp3 and its effect on regulatory T cell function. J Immunol 192(6):2892CrossRefPubMed Mu J et al (2014) Regulation of MHC class I expression by Foxp3 and its effect on regulatory T cell function. J Immunol 192(6):2892CrossRefPubMed
Metadata
Title
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
Authors
Tess O’Meara
Anton Safonov
David Casadevall
Tao Qing
Andrea Silber
Brigid Killelea
Christos Hatzis
Lajos Pusztai
Publication date
01-05-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05156-5

Other articles of this Issue 1/2019

Breast Cancer Research and Treatment 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine